Author:
Böttcher R,Henderson D J P,Dulla K,van Strijp D,Waanders L F,Tevz G,Lehman M L,Merkle D,van Leenders G J L H,Baillie G S,Jenster G,Houslay M D,Hoffmann R
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (13): 1310–1319.
2. Apuhan T, Gepdiremen S, Arslan AO, Aktas G (2013) Evaluation of patients with nasal polyps about the possible association of desmosomal junctions, RORA and PDE4D gene. Eur Rev Med Pharmacol Sci 17 (19): 2680–2683.
3. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat J-P, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA (2013) Punctuated evolution of prostate cancer genomes. Cell 153 (3): 666–677.
4. Baillie GS, MacKenzie SJ, McPhee I, Houslay MD (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 131 (4): 811–819.
5. Bangma CH, Roobol MJ (2012) Defining and predicting indolent and low risk prostate cancer. Crit Rev Oncol 83 (2): 235–241.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献